Palovarotene
Orphan DrugFDA Approved
Description
Palovarotene is a retinoic acid receptor gamma (RARγ) selective agonist used to treat fibrodysplasia ossificans progressiva (FOP). It works by reducing new heterotopic ossification (HO) volume in patients with FOP.
Indications & Therapeutic Use
Fibrodysplasia Ossificans Progressiva
Linked Diseases:
Global Availability (1 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Palovarotene
| Generic Name | Palovarotene |
| Brands | 1 brand available |
| Active Ingredient | Palovarotene |
| Drug Class | Fibrodysplasia Ossificans Progressiva |
| Manufacturer | Ipsen |
| Dosage Forms | Capsule |
| Medical Code | M04AA05 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT03997618 |
| Countries | 1 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations2 Validated Nodes